MoonLake Immunotherapeutics (MLTX) Profit After Tax Growth (3y) (2024 - 2026)

MoonLake Immunotherapeutics (MLTX) Profit After Tax Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.30%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 10.23%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 91.31%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 37.89%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 90.66%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -38.56%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 37.44%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 59.34%
10 MoonLake Immunotherapeutics 1.40 Bn 864.68 Mn - -71.03%

Historic Data

Download Data
DateValue
Jun 30, 2026 -71.03%
Mar 31, 2026 -78.92%
Dec 31, 2025 -61.92%
Sep 30, 2025 -68.06%
Jun 30, 2025 -47.64%
Mar 31, 2025 -36.00%
Dec 31, 2024 6.89%
Sep 30, 2024 -79.09%
Jun 30, 2024 8.84%
Mar 31, 2024 -241.25%